Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 121
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
BMC Med Imaging ; 23(1): 215, 2023 12 18.
Artículo en Inglés | MEDLINE | ID: mdl-38110909

RESUMEN

PURPOSE: Retroperitoneal liposarcoma (RLPS) poses a challenging scenario for surgeons due to its unpredictable biological behavior. Surgery remains the primary curative option for RLPS; however, the need for additional information to guide surgical strategies persists. Volume-based 18F-FDG PET/CT may solve this issue. METHODS: We analyzed data from 89 RLPS patients, measuring metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) and explored their associations with clinical, prognostic, and pathological factors. RESULTS: MTV, TLG of multifocal and recurrent RLPS were significantly higher than unifocal and primary ones (P < 0.001, P < 0.001, P = 0.003 and P = 0.002, respectively). SUVmax correlated with FNCLCC histological grade, mitotic count and Ki-67 index (P for G1/G2 = 0.005, P for G2/G3 = 0.017, and P for G1/G3 = 0.001, P < 0.001 and P = 0.024, respectively). MTG, TLG and SUVmax of WDLPS were significantly lower than DDLPS and PLPS (P for MTV were 0.009 and 0.022, P for TLG were 0.028 and 0.048, and P for SUVmax were 0.027 and < 0.001, respectively). Multivariable Cox analysis showed that MTV > 457.65 (P = 0.025), pathological subtype (P = 0.049) and FNCLCC histological grade (P = 0.033) were related to overall survival (OS). CONCLUSIONS: Our findings indicate that MTV is an independent prognostic factor for RLPS, while MTV, TLG, and SUVmax can preoperatively predict multifocal lesions, histological grade, and pathological subtype. Volume-based 18F-FDG PET/CT offers valuable information to aid in the decision-making process for RLPS surgical strategies.


Asunto(s)
Fluorodesoxiglucosa F18 , Tomografía Computarizada por Tomografía de Emisión de Positrones , Humanos , Estudios Retrospectivos , Pronóstico , Carga Tumoral , Radiofármacos
2.
BMC Surg ; 23(1): 189, 2023 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-37403109

RESUMEN

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Distant metastasis has been detected in approximately 50% of GIST patients at the first diagnosis. The surgical strategy for metastatic GIST with generalized progression (GP) after imatinib therapy remains unclear. METHODS: We recruited 15 patients with imatinib-resistant metastatic GIST. They received cytoreductive surgery (CRS) for tumor rupture, intestinal obstruction and gastrointestinal bleeding. We collected clinical, pathological and prognostic data for analyses. RESULTS: OS and PFS after R0/1 CRS were 56.88 ± 3.47 and 26.7 ± 4.12 months, respectively, when compared with 26 ± 5.35 and 5 ± 2.78 months after R2 CRS (P = 0.002 and P < 0.001, respectively). The OS of patients from the initiation of imatinib in the R0/1 group was 133.90 ± 15.40 months when compared with 59.80 ± 10.98 months in the R2 CRS group. There were two significant grade III complications after 15 operations (13.3%). No patient underwent reoperation. In addition, no perioperative death occurred. CONCLUSIONS: R0/1 CRS is highly probable to provide prognostic benefits for patients with metastatic GIST who experience GP following imatinib treatment. An aggressive surgical strategy for achieving R0/1 CRS can be deemed safe. If applicable, R0/1 CRS should be carefully considered in imatinib-treated patients with GP metastatic GIST.


Asunto(s)
Antineoplásicos , Neoplasias Gastrointestinales , Tumores del Estroma Gastrointestinal , Humanos , Mesilato de Imatinib/uso terapéutico , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Tumores del Estroma Gastrointestinal/cirugía , Tumores del Estroma Gastrointestinal/patología , Pronóstico , Estudios Retrospectivos , Antineoplásicos/uso terapéutico , Neoplasias Gastrointestinales/tratamiento farmacológico , Neoplasias Gastrointestinales/cirugía , Neoplasias Gastrointestinales/diagnóstico , Procedimientos Quirúrgicos de Citorreducción
3.
Int J Mol Sci ; 23(17)2022 Aug 29.
Artículo en Inglés | MEDLINE | ID: mdl-36077199

RESUMEN

Ultraviolet-C (UV-C) radiation significantly impacts living organisms. UV-C radiation can also be used as a pest management tool. Therefore, this study was designed to investigate the effect of UV-C radiation on the physiology and gene expression level of Plutella xylostella, a destructive vegetable pest. Results showed that, after exposure to UV-C radiation for 3, 6, 12, and 24 h, the activity of SOD (superoxide dismutase) and CAT (catalase) of P. xylostella increased, while the activity of PPO (polyphenol oxidase), POD (peroxidase), AChE (acetylcholinesterase), CarE (carboxylesterase), and ACP (acid phosphatase) decreased with increased exposure time. Correlation coefficient analyses indicated that the activity of CAT correlated positively, while PPO and CarE correlated negatively, with exposure time. Gene regulation analysis via qRT-PCR confirmed a significant increase in regulation in CAT, CarE, and PPO-related genes. We also investigated the effect of UV-C exposure on the virulence of Cordyceps fumosorosea against P. xylostella. Here, results indicated that when the fungal treatment was applied to larvae before UV-C radiation, the virulence of C. fumosorosea was significantly reduced. However, this decline in virulence of C. fumosorosea due to UV-C exposure remained only for one generation, and no effect was observed on secondary infection. On the other hand, when larvae were exposed to UV-C radiation before fungal application, the mortality rate significantly increased as the exposure time to UV-C radiation increased. From the current study, it could be concluded that UV-C exposure suppressed the immunity to P. xylostella, which later enhanced the virulence of entomopathogenic fungi. Moreover, the study also suggested that UV irradiation is an effective pest management tool that could be incorporated into pest management strategies, which could help reduce pesticide application, be economically beneficial for the farmer, and be environmentally safe.


Asunto(s)
Cordyceps , Mariposas Nocturnas , Acetilcolinesterasa , Animales , Larva/microbiología , Mariposas Nocturnas/microbiología
4.
Zhonghua Nan Ke Xue ; 27(11): 1025-1029, 2021 Nov.
Artículo en Zh | MEDLINE | ID: mdl-37422876

RESUMEN

Benign prostatic hyperplasia (BPH) is a chronic disease, and its exact pathogenesis is not fully clear. Nuclear factor-kappa B (NF-κB), a regulatory factor that can specifically bind target genes and mediate their transcription and expression, is characterized by wide distribution and multiple functions and gradually becoming a hotspot in studies of abnormal cell proliferation-associated diseases and inflammatory diseases. Recent studies have shown that NF-κB is involved in the growth and development of hormone-dependent organs, such as the prostate, by regulating inflammatory response, disturbing endogenous hormone levels and interfering with cell apoptosis. However, few reports are seen on the relationship between NF-κB signaling pathways and BPH. This review outlines the activation of NF-κB and its regulatory pathways in BPH, expecting to provide some reference for the prevention and treatment of BPH.

5.
Int J Med Sci ; 17(18): 3073-3081, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33173428

RESUMEN

Patient-derived xenograft (PDX) models are effective preclinical cancer models that reproduce the tumor microenvironment of the human body. The methods have been widely used for drug screening, biomarker development, co-clinical trials, and personalized medicine. However, the low success rate and the long tumorigenesis period have largely limited their usage. In the present studies, we compared the PDX establishment between hepatocellular cancer (HCC) and metastatic liver cancer (MLC), and identified the key factors affecting the transplantation rate of PDXs. Surgically resected tumor specimens obtained from patients were subcutaneously inoculated into immunodeficient mice to construct PDX models. The overall transplantation rate was 38.5% (20/52), with the HCC group (28.1%, 9/32) being lower than MLC group (56.2%, 9/16). In addition, HCC group took significantly longer latency period than MLC group to construct PDX models. Hematoxylin and eosin staining results showed that the histopathology of all generations in PDX models was similar to the original tumor in all three types of cancer. The transplantation rate of PDX models in HCC patients was significantly associated with blood type (P=0.001), TNM stage (P=0.023), lymph node metastasis (P=0.042) and peripheral blood CA19-9 level (P=0.049), while the transplantation rate of PDX models in MLC patients was significantly associated with tumor size (P=0.034). This study demonstrates that PDX models can effectively reproduce the histological patterns of human tumors. The transplantation rate depends on the type of original tumor. Furthermore, it shows that the invasiveness of the original liver cancer affects the possibility of its growth in immunodeficient mice.


Asunto(s)
Carcinoma Hepatocelular/patología , Neoplasias Colorrectales/patología , Neoplasias Hepáticas/secundario , Hígado/patología , Microambiente Tumoral , Animales , Carcinoma Hepatocelular/cirugía , Neoplasias Colorrectales/cirugía , Femenino , Hepatectomía , Humanos , Hígado/cirugía , Neoplasias Hepáticas/cirugía , Masculino , Ratones , Persona de Mediana Edad , Ensayos Antitumor por Modelo de Xenoinjerto/métodos
6.
BMC Urol ; 20(1): 177, 2020 Nov 02.
Artículo en Inglés | MEDLINE | ID: mdl-33138801

RESUMEN

BACKGROUND: Ureteric stricture is a common and salvaging complications after renal transplantation. Two treatment methods are usually used, retrograde ureteral stent placement and percutaneous nephrostomy. The former has a higher failure rate, the latter has a great risk. Therefore, a safe and reliable treatment is needed. CASE PRESENTATION: A technique of retrograde insertion of ureteral stent was established, which was applicable in three transplant recipients with post-transplant ureteral stenosis, and the data was retrospectively recorded. The patients are 2 men and 1 woman, ages 44, 27 and 32 years. These patients underwent a total of five times of retrograde insertion of ureteral stent between 2018 and 2019. None of these patients had any postoperative complication, but all patients had complete recovery from oliguric status within two weeks. CONCLUSIONS: The retrograde ureteric stent insertion by percutaneous suprapubic access to the bladder (RUS-PSAB) was demonstrated feasibility and safety in a case series with short-term follow-up. However, larger prospective studies are needed.


Asunto(s)
Trasplante de Riñón , Complicaciones Posoperatorias/cirugía , Implantación de Prótesis/métodos , Stents , Uréter/cirugía , Obstrucción Ureteral/cirugía , Adulto , Constricción Patológica/cirugía , Femenino , Humanos , Masculino , Procedimientos Quirúrgicos Mínimamente Invasivos , Vejiga Urinaria , Procedimientos Quirúrgicos Urológicos/métodos
7.
Molecules ; 25(8)2020 Apr 16.
Artículo en Inglés | MEDLINE | ID: mdl-32316104

RESUMEN

Multi-target ligand strategies provide a valuable method of drug design. However, to develop a multi-target drug with the desired profile remains a challenge. Herein, we developed a computational method binding-site match maker (BSMM) for the design of multi-target ligands based on binding site matching. BSMM was built based on geometric hashing algorithms and the representation of a binding-site with physicochemical (PC) points. The BSMM software was used to detect proteins with similar binding sites or subsites. In particular, BSMM is independent of protein global folds and sequences and is therefore applicable to the matching of any binding sites. The similar sites between protein pairs with low homology and/or different folds are generally not obvious to the visual inspection. The detection of such similar binding sites by BSMM could be of great value for the design of multi-target ligands.


Asunto(s)
Biología Computacional/métodos , Proteínas/química , Sitios de Unión , Diseño de Fármacos , Ligandos , Modelos Moleculares , Unión Proteica , Programas Informáticos
8.
Pak J Pharm Sci ; 32(1(Special)): 459-464, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30852485

RESUMEN

.To explore the clinicopathological features of solid pseudopapillary neoplasm (SPN) of pancreas and to analyze the related factors of SPNs with aggressive behavior. Clinical data of SPN patients admitted in the Single Center of Peking University Cancer Hospital from January 2007 to September 2017 were retrospectively analyzed. The correlations of clinicopathological features with aggressive SPNs and distant metastasis after curative resection were analyzed using univariate analysis. Twelve of the total 54 SPN patients were diagnosed as aggressive SPNs. Univariate analysis suggested clinical features had no correlations with aggressive SPNs. Patients were followed up for an average of 5.0 years, four of them developed distant metastases. Univariate analysis indicated that distant metastasis of SPNs was correlated with the aggressive behaviors (P=0.031). Moreover, vessels invasion (VI) and Ki-67>4% (P=0.012) were the independent risk factors of distant metastasis of SPNs. The aggressive SPNs, especially VI and Ki-67>4% are the independent factors correlated with distant metastases after SPNs surgery.


Asunto(s)
Carcinoma Papilar/patología , Páncreas/patología , Neoplasias Pancreáticas/patología , Adolescente , Adulto , Anciano , Carcinoma Papilar/diagnóstico por imagen , Carcinoma Papilar/epidemiología , Carcinoma Papilar/cirugía , Niño , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Páncreas/diagnóstico por imagen , Páncreas/cirugía , Pancreatectomía , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/epidemiología , Neoplasias Pancreáticas/cirugía , Pronóstico , Supervivencia sin Progresión , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Adulto Joven
9.
Mol Ther ; 25(2): 416-426, 2017 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-28153092

RESUMEN

Hematopoietic stem cells (HSCs) have the capacity to self-renew and differentiate into hematopoietic cells and have been utilized to replace diseased bone marrow for patients with cancers and blood disorders. Although remarkable progress has been made in developing new tools to manipulate HSCs for clinic use, there is still no effective method to expand HSCs in vivo for quick repopulation of hematopoietic cells following sublethal irradiation. We have recently described a novel synthetic cytokine that is derived from the fusion of granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4; named as GIFT4), and we have now discovered that GIFT4 fusokine promotes long-term hematopoietic regeneration in a B cell-dependent manner. We found that GIFT4 treatment triggered a robust expansion of endogenous bone marrow HSCs and multipotent progenitors in vivo. Delivery of GIFT4 protein together with B cells rescued lethally irradiated mice. Moreover, adoptive transfer of autologous or allogeneic GIFT4-treated B cells (GIFT4-B cells) enhanced long-term hematopoietic recovery in radiated mice and prevented the mice from irradiation-induced death. Our data suggest that GIFT4 as well as GIFT4-B cells could serve as means to augment HSC engraftment in the setting of bone marrow transplantation for patients with hematological malignancy.


Asunto(s)
Linfocitos B/citología , Linfocitos B/efectos de los fármacos , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Interleucina-4 , Linfopoyesis/efectos de los fármacos , Proteínas Recombinantes de Fusión/farmacología , Animales , Linfocitos B/metabolismo , Biomarcadores , Células de la Médula Ósea/efectos de los fármacos , Células de la Médula Ósea/metabolismo , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Citocinas/metabolismo , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Células Madre Hematopoyéticas/citología , Células Madre Hematopoyéticas/efectos de los fármacos , Células Madre Hematopoyéticas/metabolismo , Inmunofenotipificación , Interleucina-4/genética , Masculino , Ratones , Modelos Animales , Fenotipo , Proteínas Recombinantes de Fusión/genética
10.
Med Sci Monit ; 24: 961-969, 2018 Feb 16.
Artículo en Inglés | MEDLINE | ID: mdl-29449525

RESUMEN

BACKGROUND There is no standard surgical approach for the management of retroperitoneal sarcoma. The aim of this clinical study was to describe the experience of an anterior approach to en bloc resection in left-sided retroperitoneal sarcoma with adjacent organ involvement. MATERIAL AND METHODS This retrospective clinical study included 25 patients who were diagnosed with left-sided retroperitoneal sarcoma and underwent tumor resection at a single center between May 2012 and July 2017. All patients had tumors that were adjacent to the left colon, pancreas, left kidney, left adrenal gland, and psoas major; some of the tumors were adjacent to the diaphragm, stomach, and small intestine. An anterior approach was used to remove the left-sided retroperitoneal tumor with the adhesive organs en bloc, an approach that is described in detail. The value of this surgical approach was evaluated based on the histopathological findings, postoperative complications, and patient follow-up. RESULTS The median number of resected organs, in addition to the retroperitoneal tumor, was 8 (range, 6-10). Complete macroscopic tumor resection was achieved in 23 cases (92%). Twenty-four patients (96%) had tumor infiltration of at least one organ or the surrounding fat. Three patients (12%) experienced Grade III and IV postoperative morbidities. The one-year disease-free survival rate was 91.3% among patients with macroscopically complete resections. The one-year overall survival rate was 83.2%. CONCLUSIONS In selected patients, left-sided retroperitoneal sarcoma associated with local organ involvement can be surgically managed using an anterior approach with en bloc resection of adjacent organs.


Asunto(s)
Especificidad de Órganos , Neoplasias Retroperitoneales/cirugía , Sarcoma/cirugía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Cuidados Posoperatorios , Neoplasias Retroperitoneales/diagnóstico por imagen , Neoplasias Retroperitoneales/epidemiología , Sarcoma/diagnóstico por imagen , Sarcoma/epidemiología , Tomografía Computarizada por Rayos X
11.
Dig Surg ; 35(6): 532-538, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29275422

RESUMEN

AIMS: To compare the short- and long-term outcomes in patients with pancreatic benign or borderline neoplasm who underwent central pancreatectomy (CP) and distal pancreatectomy (DP). METHODS: The inclusion criteria were as follows: (1) single benign or low-grade malignant tumor; (2) tumor confined to the pancreatic neck or proximal body; and (3) tumor amenable to either CP or DP. Short and long-term outcomes, including complications, pancreatic exocrine and endocrine function, and quality of life (QoL) were analyzed retrospectively. RESULTS: Sixteen patients who underwent CP and 26 patients who underwent DP were included. The median follow-up period was 53 months (range 21-117 months). Patients undergoing CP were significantly more likely to experience complications (68.7 vs. 23%, p = 0.003) especially grade B/C postoperative pancreatic fistula (62.5 vs. 23%, p = 0.011) than those undergoing DP. During the long-term follow-up, 2 patients in the DP group developed new-onset diabetes mellitus, but no patient in CP group developed this condition (8 vs. 0%, p = 0.382). Evidence of exocrine insufficiency, including severe diarrhea or steatorrhea, was not observed in either group. Both groups were equally satisfied with the overall health status and overall QoL. CONCLUSION: CP is associated with excellent pancreatic function but a significantly increased postoperative morbidity and risk compared to DP. Therefore, the indication of CP should be chosen strictly.


Asunto(s)
Pancreatectomía/métodos , Fístula Pancreática/etiología , Neoplasias Pancreáticas/patología , Neoplasias Pancreáticas/cirugía , Adulto , Diabetes Mellitus/etiología , Insuficiencia Pancreática Exocrina/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Páncreas/fisiopatología , Pancreatectomía/efectos adversos , Satisfacción del Paciente , Complicaciones Posoperatorias/etiología , Calidad de Vida , Estudios Retrospectivos , Resultado del Tratamiento
12.
Biomed Environ Sci ; 30(9): 641-648, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29081338

RESUMEN

OBJECTIVE: To evaluate whether mono (2-ethylhexyl) phthalate (MEHP) affects genomic DNA methylation and the methylation status of some specific genes such as patched gene (PTCH) and smoothened gene (SMO) in LNCaP cells. METHODS: LNCaP cells were treated with MEHP (0, 1, 5, 10, and 25 µmol/L) for 3 days. An ELISA assay was preformed to detect genomic methylation, including 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) content. A pyrosequencing assay was applied to assess DNA methylation in PTCH and SMO gene promoters. The correlation between DNA methylation and gene expression was assessed. RESULTS: The proportion of cytosines with 5-mC methylation in LNCaP cells was significantly decreased by MEHP (1, 5, 10, and 25 µmol/L) in a dose-dependent manner (P < 0.01). For genes in the Hedgehog pathway, there was no significant MEHP concentration-dependent difference in the DNA methylation of PTCH and SMO. CONCLUSION: MEHP might affect the progression of prostate cancer through its effect on global DNA methylation.


Asunto(s)
Antineoplásicos/farmacología , Metilación de ADN , Ácidos Ftálicos/química , Neoplasias de la Próstata/metabolismo , Antineoplásicos/química , Línea Celular Tumoral , Humanos , Masculino
13.
Zhonghua Nan Ke Xue ; 23(7): 663-667, 2017 Jul.
Artículo en Zh | MEDLINE | ID: mdl-29723463

RESUMEN

Prostaglandin synthase (PGS) can catalyze the production of various types of prostaglandins and regulate the expression levels of related substances. The regulation mechanisms of the PGS gene are closely related with the occurrence and development of prostate diseases. However, few studies are reported on the regulation mechanisms of PGS in prostatic diseases, such as benign prostatic hyperplasia (BPH) and prostate cancer (PCa), or on the relationship between PGS gene regulation and prostate diseases. This review aims to analyze their correlation and provide some ideas for the prevention and control of BPH and PCa by intervention of the prostaglandin synthase regulatory pathway.


Asunto(s)
Regulación de la Expresión Génica , Prostaglandina-Endoperóxido Sintasas/genética , Hiperplasia Prostática/prevención & control , Neoplasias de la Próstata/prevención & control , Humanos , Masculino , Prostaglandina-Endoperóxido Sintasas/fisiología , Hiperplasia Prostática/enzimología , Hiperplasia Prostática/genética , Neoplasias de la Próstata/enzimología , Neoplasias de la Próstata/genética
14.
J Transl Med ; 14(1): 106, 2016 04 27.
Artículo en Inglés | MEDLINE | ID: mdl-27118475

RESUMEN

BACKGROUND: Chronic lymphocytic leukemia (CLL) remains incurable with standard therapy, and is characterized by excessive expansion of monoclonal abnormal mature B cells and more regulatory immune properties of T cell compartment. Thus, developing novel strategies to enhance immune function merits further investigation as a possible therapy for CLL. METHODS: We generated a fusion cytokine (fusokine) arising from the combination of human GM-CSF and IL-4 (named GIFT4). Primary CLL cells were treated with GIFT4 or GM-CSG and IL-4 in vitro. GIFT4-triggered STAT5 signaling in CLL cells was examined by Western blot. The phenotype and secretome of GIFT4-treated CLL cells (GIFT4-CLL cells), and the immune stimulatory function of GIFT4-CLL cells on autologous T cells were analyzed by flow cytometry and luminex assay. RESULTS: GIFT4-CLL up-regulated the expression of co-stimulatory molecules CD40, CD80 and CD86 and adhesion molecule CD54. GIFT4-CLL cells secreted IL-1ß, IL-6, ICAM-1 and substantial IL-2 relative to unstimulated CLL cells. GIFT4 treatment led to JAK1, JAK2 and JAK3-mediated hyper-phosphorylation of STAT5 in primary CLL cells, which is essential for GIFT4-triggered conversion of CLL cells. GIFT4-CLL cells directly propelled the expansion of autologous IFN-γ-producing CD314(+) cytotoxic T cells in vitro, and that these could lyse autologous CLL cells. Furthermore, administration of GIFT4 protein promoted the expansion of human T cells in NOD-scid IL2Rγ(null) immune deficient mice adoptively pre-transferred with peripheral blood mononuclear cells from subjects with CLL. CONCLUSION: GIFT4 has potent capability to converts primary CLL cells into APC-like immune helper cells that initiate a T cell driven anti-CLL immune response.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Interleucina-4/farmacología , Leucemia Linfocítica Crónica de Células B/inmunología , Leucemia Linfocítica Crónica de Células B/patología , Proteínas Recombinantes de Fusión/farmacología , Linfocitos T Colaboradores-Inductores/inmunología , Adulto , Anciano , Animales , Células Presentadoras de Antígenos/efectos de los fármacos , Células Presentadoras de Antígenos/metabolismo , Proliferación Celular/efectos de los fármacos , Reactividad Cruzada/efectos de los fármacos , Citotoxicidad Inmunológica/efectos de los fármacos , Femenino , Humanos , Quinasas Janus/metabolismo , Masculino , Ratones , Persona de Mediana Edad , Fenotipo , Proteoma/metabolismo , Factor de Transcripción STAT5/metabolismo , Transducción de Señal/efectos de los fármacos , Linfocitos T Colaboradores-Inductores/citología , Linfocitos T Colaboradores-Inductores/efectos de los fármacos
15.
Biochim Biophys Acta ; 1830(5): 3350-3, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23201199

RESUMEN

BACKGROUND: Glutathione (GSH) and related enzymes are critical to cell protection from toxins, both endogenous and environmental, including a number of anti-cancer cytotoxic agents. SCOPE OF REVIEW: Enhancing GSH and associated enzymes represents a longtime and persistent aim in the search for cytoprotective strategies against cancer, neurologic degeneration, pulmonary and inflammatory conditions, as well as cardiovascular ailments. The challenge is to identify effective GSH analogues or precursors that generate mimic molecules with glutathione's cellular protective effects. This review will provide an update on these efforts. Much effort has also been directed at depleting cellular GSH and related cytoprotective effects, in order to sensitize established tumors to the cytotoxic effects of anti-cancer agents. Efforts to deplete GSH have been limited by the challenge of selectivity doing so in tumor and not in normal tissue so as to avoid enhancing the toxicity of anti-cancer drugs. This review will also provide an update of efforts at overcoming the challenge of targeting the desired GSH depletion to tumor cells. MAJOR CONCLUSIONS: This chapter provides a brief background and update of progress in the development and use of GSH analogues in the therapeutic setting, including the pharmacological aspects of these compounds. GENERAL SIGNIFICANCE: This is an area of enormous research activity, and major advances promise the advent of novel therapeutic opportunities in the near future. This article is part of a Special Issue entitled Cellular functions of glutathione.


Asunto(s)
Glutatión/análogos & derivados , Glutatión/farmacología , Glutatión/uso terapéutico , Animales , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Citoprotección , Humanos , Neoplasias/tratamiento farmacológico
16.
Invest New Drugs ; 32(2): 227-34, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24146017

RESUMEN

Current therapeutic strategy for advanced prostate cancer is to suppress the androgen receptor (AR) signaling. However, lethal castration-resistant prostate cancer (CRPC) arises due to AR reactivation via multiple mechanisms, including mutations in the AR and cross-talk with other pathways such as NF-κB. We have previously identified two ionone-based antiandrogens (SC97 and SC245), which are full antagonists of the wild type and the clinically-relevant T877A, W741C and H874Y mutated ARs. Here, we discovered SC97 and SC245 also inhibit NF-κB. By synthesizing a series of derivatives of these two compounds, we have discovered a novel compound 3b that potently inhibits both AR and NF-κB signalling, including the AR F876L mutant. Compound 3b showed low micromolar antiproliferative activites in C4-2B and 22Rv1 cells, which express mutated ARs and are androgen-independent, as well as DU-145 and PC-3 cells, which exhibit constitutively activated NF-κB signalling. Our studies indicate 3b is effective against the CRPC cells.


Asunto(s)
Antagonistas de Receptores Androgénicos/farmacología , Antineoplásicos/farmacología , FN-kappa B/antagonistas & inhibidores , Norisoprenoides/farmacología , Antagonistas de Receptores Androgénicos/síntesis química , Antineoplásicos/síntesis química , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Células HEK293 , Humanos , Interleucina-6/antagonistas & inhibidores , Masculino , Norisoprenoides/síntesis química , Neoplasias de la Próstata Resistentes a la Castración/metabolismo , Receptores Androgénicos/metabolismo
17.
Tumour Biol ; 35(7): 7057-62, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24756758

RESUMEN

Genetic polymorphism of endothelial nitric oxide synthase (NOS3) rs1799983 (Glu298Asp) has been implicated to alter the risk of prostate cancer, but the results are controversial. Two investigators independently searched the PubMed, Cochrane Library, and Embase electronic databases up to September 30, 2013. Summary odds ratios (OR) and 95 % confidence interval (CI) for rs1799983 polymorphism and prostate cancer were calculated. Statistical analysis was performed with the software program Review Manage, version 5.0 and Stata 11.0. A total of 7 independent studies, including 1,792 cases and 2,411 controls, were identified. Our analysis suggested that rs1799983 was associated with prostate cancer risk in overall population under dominant model (OR = 1.15, 95%CI = 1.01-1.30, P = 0.03) and allelic model (OR = 1.11, 95%CI = 1.00-1.22, P = 0.04). In the subgroup analysis, we detected no association between rs1799983 polymorphism and prostate risk in Caucasian population under all the genetic models. This meta-analysis showed the evidence that NOS3 rs1799983 polymorphism was associated with a risk of prostate cancer development in overall populations.


Asunto(s)
Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Óxido Nítrico Sintasa de Tipo III/genética , Neoplasias de la Próstata/genética , Estudios de Casos y Controles , Humanos , Masculino , Polimorfismo de Nucleótido Simple , Neoplasias de la Próstata/patología
18.
Mol Ther ; 21(11): 2043-53, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23985699

RESUMEN

Preclinical and clinical trials demonstrated that use of oncolytic viruses (OVs) is a promising new therapeutic approach to treat multiple types of cancer. To further improve their viral oncolysis, experimental strategies are now combining OVs with different cytotoxic compounds. In this study, we investigated the capacity of triptolide - a natural anticancer molecule - to enhance vesicular stomatitis virus (VSV) oncolysis in OV-resistant cancer cells. Triptolide treatment increased VSV replication in the human prostate cancer cell line PC3 and in other VSV-resistant cells in a dose- and time-dependent manner in vitro and in vivo. Mechanistically, triptolide (TPL) inhibited the innate antiviral response by blocking type I interferon (IFN) signaling, downstream of IRF3 activation. Furthermore, triptolide-enhanced VSV-induced apoptosis in a dose-dependent fashion in VSV-resistant cells, as measured by annexin-V, cleaved caspase-3, and B-cell lymphoma 2 staining. In vivo, using the TSA mammary adenocarcinoma and PC3 mouse xenograft models, combination treatment with VSV and triptolide delayed tumor growth and prolonged survival of tumor-bearing animals by enhancing viral replication. Together, these results demonstrate that triptolide inhibition of IFN production sensitizes prostate cancer cells to VSV replication and virus-mediated apoptosis.


Asunto(s)
Diterpenos/farmacología , Interferones/metabolismo , Neoplasias/terapia , Viroterapia Oncolítica/métodos , Virus Oncolíticos/fisiología , Fenantrenos/farmacología , Transducción de Señal/efectos de los fármacos , Virus de la Estomatitis Vesicular Indiana/fisiología , Animales , Antineoplásicos Alquilantes/farmacología , Apoptosis , Línea Celular Tumoral , Terapia Combinada , Compuestos Epoxi/farmacología , Femenino , Células HEK293 , Humanos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias/inmunología , Neoplasias/virología , Neoplasias Experimentales , Virus Oncolíticos/genética , Virus Oncolíticos/inmunología , Virus de la Estomatitis Vesicular Indiana/genética , Virus de la Estomatitis Vesicular Indiana/inmunología , Replicación Viral , Ensayos Antitumor por Modelo de Xenoinjerto
20.
Zhonghua Nan Ke Xue ; 20(2): 181-5, 2014 Feb.
Artículo en Zh | MEDLINE | ID: mdl-24520675

RESUMEN

Benign prostatic hyperplasia (BPH) is a worldwide common disease in men over 50 years old, and the exact cause of BPH remains largely unknown. In order to elucidate its pathogenesis and screen effective drugs for the treatment of BPH, many BPH models have been developed at home and abroad. This article presents a comprehensive analysis of the categories and characteristics of BPH drug evaluation models, highlighting the application value of each model, to provide a theoretical basis for the development of BPH drugs.


Asunto(s)
Diseño de Fármacos , Evaluación de Medicamentos , Animales , Modelos Animales de Enfermedad , Masculino , Hiperplasia Prostática/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA